Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patrys, a biopharmaceutical company focused on the development of natural human antibodies for the treatment of cancer, has released its schedule for the clinical development of its product PAT-SM6 targeting melanoma cancer cells.
Subscribe to our email newsletter
Patrys said that an application for approval to commence a human clinical trial for PAT-SM6 has been lodged with Australian authorities, with the aim of initiating the trial in the next 30 to 60 days. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule and its disease target GRP78.
Patrys stated that PAT-SM6 will represent the second product from its pipeline evaluated in a human clinical trial. PAT-SC1, a natural human antibody evaluated in a gastric cancer human clinical trial, was shown to provide treated patients with a survival rate that was higher than untreated patients. A larger trial for PAT-SC1 is expected to commence in calendar year 2011.
Melanoma has been selected as the first indication for PAT-SM6 based on the data that has been generated showing that PAT-SM6 is effective at killing melanoma cancer cells and binding to 100% of all melanoma patient tumours screened.
Patrys added that the first human clinical trial for PAT-SM6 is expected to aim to treat patients with melanoma. The study’s primary endpoints are expected to be related to safety and tolerability. First patient data is expected in the third quarter of calendar year 2010. The trial is expected to take approximately 12 months during which time PAT-SM6 will also be assessed for its ability to effectively target melanoma tumours.
Dan Devine, CEO of Patrys, said: “This is exciting for the company and the patients we aim to treat as it marks the commencement of the clinical development of PAT-SM6.
“Longer-term, we now have a technology platform that can be applied to treat many cancers through the advancement of several products into the clinic in a timely manner.”